Amgen Inc. (ISIN US0311621009) stock is trading close to its recent level in mid-August 2026 as investors weigh a higher analyst price target against a strategic reset in the company’s obesity drug pipeline, highlighted on August 17, 2026 by new industry reporting. One recent note lifted the 12?month price objective on Amgen shares to $380, pointing to upside of roughly mid?single digits from the latest closing price and underscoring expectations that newer assets can sustain growth as legacy products mature.
Analyst lifts target as shares hover above $400
Market data for August 14, 2026 show Amgen shares closing at $415.21 on Nasdaq, with an unchanged session move that left the stock flat on the day. In the same data, extended trading after the closing bell showed the price easing slightly to $414.50 by 7:52 p.m. Eastern Time, a marginal decline of 0.17% from the official close that still kept the stock well above the $400 mark. Against this backdrop, a recent analyst note raising the price objective to $380 indicates that the latest quote stands more than $35 above that target, suggesting the market is already discounting considerable optimism or assigning a valuation premium for pipeline progress.
The gap between the $415.21 close on August 14, 2026 and the $380 price target represents an implied downside of about 8.5%, a reversal from earlier periods when price goals often sat above the prevailing quote. For investors, this numerical comparison matters because it signals that the shares now trade above at least one published fair?value estimate, even as sentiment toward Amgen’s obesity and cardiovascular prospects remains positive. It also illustrates how quickly the market price can outrun incremental target hikes when enthusiasm for a therapeutic area builds.
Obesity pipeline reshaped with MariTide center stage
Industry coverage dated August 17, 2026 reports that Amgen has halted further development of AMG 513, an obesity drug candidate that had been in an early Phase 1 program. According to that same report, the move is framed as a decision to concentrate development resources on MariTide, Amgen’s more advanced obesity therapy that has already progressed into later?stage clinical trials. By stepping away from AMG 513 at this stage, Amgen reduces internal competition for capital and operational capacity, which can shorten timelines and potentially enhance probability of success for the lead asset.
The strategic choice to focus on MariTide also clarifies the company’s obesity franchise narrative at a time when rivals are racing through pivotal trials and scaling up commercial infrastructure for weight?management drugs. With several competitors pushing into Phase 3 obesity studies, Amgen’s decision to discontinue AMG 513 while emphasizing MariTide allows investors to concentrate on one main late?stage program rather than several earlier bets with overlapping mechanisms and higher development risk. From a risk?reward standpoint, redeploying spending from a Phase 1 candidate into a later?stage program can improve capital efficiency, especially if the lead candidate targets a large and durable market segment.
The contrast between the halted Phase 1 effort for AMG 513 and the continued late?stage development of MariTide highlights how Amgen is reshaping its R&D portfolio in favor of programs with clearer line of sight to commercialization. Where AMG 513 carried the uncertainties inherent in early?stage trials, MariTide sits closer to potential regulatory submission, so each dollar shifted from AMG 513 to MariTide has a more immediate impact on the likely timing and scale of future revenue contribution. This pipeline refocusing is one reason the stock manages to hold above $400 even though at least one published 12?month target is set at $380.
Go deeper
Recent Amgen trading overview gives a snapshot of the stock’s latest closing price and after?hours move in mid-August 2026, including the $415.21 close and the modest 0.17% decline in extended trading. For the obesity pipeline update, industry reporting on August 17, 2026 in a detailed article on obesity drug runners?up explains why Amgen elected to halt AMG 513 development and concentrate resources on MariTide as the program heads toward a Phase 3 showdown with other late?stage contenders. Investors tracking the valuation debate and target changes can find one such update in a recent target?hike summary, which notes a lift in the price objective to $380 while maintaining a neutral stance on the shares.
MariTide as a showcase of Amgen’s innovation
MariTide has become a central example of how Amgen seeks to apply its biologics expertise to high?growth therapeutic categories such as obesity. By progressing this asset into later?stage clinical trials while stepping back from AMG 513, the company is signaling that MariTide currently offers the clearest path to commercial entry in the competitive weight?management space. The program’s advancement into pivotal studies places it in direct comparison with leading obesity therapies under development elsewhere, raising the stakes for trial outcomes on key efficacy and safety endpoints.
For patients and payers, a successful MariTide program could expand treatment options beyond currently marketed weight?loss drugs, particularly if trial readouts show a differentiated profile on weight reduction, cardiometabolic outcomes, or tolerability. From Amgen’s perspective, the addressable market for medically supervised obesity treatment is measured in tens of millions of people globally, creating the potential for multi?billion?dollar peak sales if MariTide can secure a meaningful share. That magnitude of opportunity helps explain why the market is willing to value Amgen shares above at least one published 12?month price target despite limited near?term financial contribution from the obesity portfolio.
Amgen stock valuation and late?stage pipeline balance
With Amgen stock closing at $415.21 on August 14, 2026 and one recently published price target set at $380, the valuation embeds a premium over that single target but still reflects the balance of risk between mature franchises and emerging growth drivers. The modest 0.17% decline to $414.50 in after?hours trade shows that the immediate market reaction to the obesity pipeline shift and target increase has been contained, rather than producing large swings. For investors, this stable reaction around the $415 level suggests that the news flow is being treated as an incremental adjustment rather than a transformational event.
The interplay between the halted AMG 513 program and the accelerated focus on MariTide demonstrates how Amgen is managing its late?stage pipeline to support future revenue and earnings trajectories. If MariTide’s clinical data ultimately support regulatory approval and broad reimbursement, its contribution could help offset pricing pressure and biosimilar competition affecting older products. In that scenario, the currently observed gap of more than $35 between the stock price and the $380 target might close through either earnings growth that validates the higher trading level or through a normalization in the share price if expectations soften.
Fact box
Company: Amgen Inc.ISIN: US0311621009Ticker: AMGNExchange: NasdaqSector / Industry: Health care / Biotechnology
Disclaimer…
en | US0311621009 | AMGEN | boerse | 69956749 | bgmi
